Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.

Dabholkar MD, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, Yu JJ, Silber JR, Reed E.

Mol Carcinog. 1996 Sep;17(1):1-7.

PMID:
8876669
2.

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.

Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E.

Cancer Res. 1995 Mar 15;55(6):1261-6.

3.

Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.

Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM.

Cancer Res. 1993 Aug 15;53(16):3694-9.

4.

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.

Cancer Res. 1993 Jan 15;53(2):242-7.

5.

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.

Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E.

Carcinogenesis. 1991 Jul;12(7):1253-8.

PMID:
2070490

Supplemental Content

Loading ...
Support Center